FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 353:1416-1417 September 29, 2005 Number 13 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Kralovics, R. PubMed Citation

To the Editor: An activating somatic mutation involving the JH2 pseudokinase domain of Janus kinase 2 (JAK2 [V617F]) has been associated with myeloproliferative disorders. The mutation is detectable in 65 percent¹ to 97 percent² of cases of polycythemia vera. Kralovics and colleagues (April 28 issue)¹ report a significant association between homozygosity for the JAK2 (V617F) mutation, which occurred in approximately one quarter of the patients with polycythemia vera, and increased duration of disease in polycythemia vera, essential thrombocythemia, and myelofibrosis with myeloid metaplasia. A similar observation was made by others,³ raising the possibility that homozygosity for the mutant . . . [Full Text of this Article]

This article has been cited by other articles:

• Vardiman, J. W., Thiele, J., Arber, D. A., Brunning, R. D., Borowitz, M. J., Porwit, A., Harris, N. L., Le Beau, M. M., Hellstrom-Lindberg, E., Tefferi, A., Bloomfield, C. D. (2009). The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 114: 937-951 [Abstract] [Full Text]  
• Gattenlohner, S., Ertl, G., Einsele, H., Kircher, S., Muller-Hermelink, H.-K., Marx, A. (2008). Cardiac JAK2 Mutation V617F in a Patient with Cardiomyopathy and Myeloproliferative Disease. ANN INTERN MED 149: 69-71 [Full Text]  
• Pardanani, A. (2007). JAK2V617F and phenotype: questions galore. Blood 109: 8-8 [Full Text]  
• Campbell, P. J., Baxter, E. J., Beer, P. A., Scott, L. M., Bench, A. J., Huntly, B. J. P., Erber, W. N., Kusec, R., Larsen, T. S., Giraudier, S., Le Bousse-Kerdiles, M.-C., Griesshammer, M., Reilly, J. T., Cheung, B. Y., Harrison, C. N., Green, A. R. (2006). Mutation of JAK2 in the myeloproliferative disorders: timing, clonality studies, cytogenetic associations, and role in leukemic transformation. Blood 108: 3548-3555 [Abstract] [Full Text]  
• Ishii, T., Bruno, E., Hoffman, R., Xu, M. (2006). Involvement of various hematopoietic-cell lineages by the JAK2V617F mutation in polycythemia vera. Blood 108: 3128-3134 [Abstract] [Full Text]  
• Lay, M., Mariappan, R., Gotlib, J., Dietz, L., Sebastian, S., Schrijver, I., Zehnder, J. L. (2006). Detection of the JAK2 V617F Mutation by LightCycler PCR and Probe Dissociation Analysis. J. Mol. Diagn. 8: 330-334 [Abstract] [Full Text]  
• Hoffman, R., Xu, M. (2006). Is bone marrow fibrosis the real problem?. Blood 107: 3421-3422 [Full Text]  
• Tefferi, A. (2006). Classification, Diagnosis and Management of Myeloproliferative Disorders in the JAK2V617F Era. ASH Education Book 2006: 240-245 [Abstract] [Full Text]